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Abstract 
Background: Retrospective and prospective observational studies are designed to reflect real-
world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF 
Registry includes both methods of enrolment and allows analysis of differences in patient 
characteristics and outcomes that may result.  
Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at 
diagnosis of AF were recruited either retrospectively (n=5069) or prospectively (n=5501) from 
19 countries and then followed prospectively.  The retrospectively enrolled cohort comprised 
patients with established AF (for a least 6, and up to 24 months before enrolment), who were 
identified retrospectively (and baseline and partial follow-up data were collected from the 
emedical records) and then followed prospectively between 0-18 months (such that the total time 
of follow-up was 24 months;  data collection Dec-2009 and Oct-2010). In the prospectively 
enrolled cohort, patients with newly diagnosed AF ( ≤6 weeks after diagnosis) were recruited 
between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences 
between the cohorts were observed in clinical characteristics, including type of AF, stroke 
prevention strategies, and event rates. More patients in the retrospectively identified cohort 
received vitamin K antagonists (62.1% vs. 53.2%) and  fewer received non-vitamin K oral 
anticoagulants (1.8% vs. 4.2%). All-cause mortality rates per 100 person-years during the 
prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the 
retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs. 4.05 [95% CI 
3.53 to 4.63]; p=0.016).  
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Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and 
outcomes of patients with AF must take account of differences in registry design and the impact 
of recall bias and survivorship bias that is incurred with retrospective enrolment. 
Clinical Trial Registration — URL: http://www.clinicaltrials.gov. Unique identifier for 
GARFIELD-AF (NCT01090362) 
 
Keywords:  Registries, Atrial Fibrillation, Anticoagulation, Retrospective, Prospective
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INTRODUCTION 
 
Observational studies are designed to reflect real-world evidence on clinical practice, but they 
can yield conflicting results. This report aims to determine some of the reasons for these 
apparent differences.  
 
The number of scientific publications indexed by MEDLINE that include ‘real-world’ in the 
title has increased by four-fold in the last decade. This increase is being driven by the needs 
of clinicians, regulators, and payers for data in unselected populations.1 Data from 
observational studies are also needed to meet regulatory expectations for labeling, pricing and 
reimbursement. Combined with evidence from RCTs, real-world data has the potential to 
influence decision makers on the care of individual patients.2-6   
 
Observational studies, including cohort studies, are longitudinal studies that aim to collect 
data on both the exposure(s) to therapy and the outcome(s) of interest but they are dependent 
on the accuracy and completeness of collected clinical data.  The most common source of 
real-world evidence is based on observational studies using routinely collected data e.g., 
cancer records, hospital episode statistics, death records. In contrast, a patient registry is an 
‘organized system that uses observational study methods to collect uniform data (clinical and 
other) to evaluate specified outcomes for a population or cohort defined by a particular 
disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, 
or policy purpose’.  For this reason, registries may collect patient characteristics and 
outcomes that may not be available from routine data collection systems.7   However, 
registries differ in their design and quality assurance, their recruitment strategies and care 
settings, and their geographic distribution and follow-up.8-12  
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Another important consideration is whether the study is prospective or retrospective. We use 
the timing of subject identification to distinguish between prospective and retrospective 
cohort studies. Studies carried out forward into the future are denoted prospective studies, 
while studies carried out looking backward into the past are denoted retrospective cohort 
studies. The most common design of registries is retrospective, where both the identification 
and outcomes of patients with AF are recorded retrospectively.   Such studies can be quick 
and relatively inexpensive and involve fewer resources and less study time than prospective 
studies, but are more susceptible to bias in both data collection and analysis and the influence 
of unidentified confounders 
 
Prospective studies provide a more robust model for collecting data because patients with 
predefined characteristics are recruited and then their outcomes are recorded as and when 
they occur over the study. 11, 13, 14 Generally, prospective studies require patient recruitment 
and informed consent (which may introduce a level of bias).  Overall, however, prospective 
studies are associated with less bias in reporting and analyses because the study design 
generally is informed by a protocol including predefined statistical analyses plans and 
outcome measures. 
 
The Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) is a 
prospective non-interventional study.3 It is designed to reflect patient management according 
to local practices. Treatment is neither mandated nor paid for by a sponsor and no additional 
visits, tests or procedures are required by the protocol. To mitigate against selection bias in 
the recruitment of patients into GARFIELD-AF and to ensure an accurate representation of 
current practice, a number of steps were taken in the design of the registry.3  One such step 
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was the analyses of data from two cohorts of patients during the first cycle of recruitment: 
firstly, a retrospective enrolment cohort of patients with “established AF” (for a least 6, and 
up to 24 months before enrolment) akin to many of the ongoing registries in AF which were 
recruting patients within 3 to 12 months of diagnosis.2, 14-16   Secondly, a prospective 
enrolment cohort of patients with “newly diagnosed AF” (enrolled within 6 weeks of 
diagnosis). Hence we were able to compare data from the first prospective cycle of 
recruitment with data from subsequent cycles, as well as with the data from patients enrolled 
retrospectively and followed prospectively.   
 
The aim of this paper is to describe the demographics, clinical characteristics, and treatment 
patterns of newly diagnosed patients who were enrolled prospectively and compare these 
with retrospectively identified patients with “established AF” (for a least 6, and up to 24 
months before enrolment). Differences in the burden of disease and outcome events were 
recorded with prospective follow-up of both cohorts.  
 
METHODS 
Registry design 
The principal aim of the GARFIELD-AF registry is to define the management strategies for 
patients with newly diagnosed AF and one or more risk factors for stroke, and relate these to 
the primary outcomes (stroke/systemic embolism [SE], major bleeding, all-cause mortality).17 
Data were captured from the time of enrolment and over 2 years of follow-up (data extraction 
date: Jul-2016). 
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Participating sites 
Investigator sites in GARFIELD-AF are representative of the distribution of care settings and 
locations (rural or urban) in each participating country.  Sufficient sites, both globally and on 
a national level, were identified from hospital, community, and anticoagulation clinic settings 
with the aim of achieving appropriate representation of AF-treating care settings in 
participating countries. The final national selection of representative sites in 19 countries was 
based on National Coordinating Investigator recommendations and sites were selected at 
random.3 A summary of the geographic location of study centres, baseline characteristics, and 
a full disclosure of the antithrombotic treatment of all patients enrolled into cohort 1 are 
given in a previously published paper.18 The paper included 44 patients who were excluded 
from the current analyses on account of subsequently identified audit violations.  
 
Data collection and statistical analyses 
Two cohorts of patients from 19 countries were evaluated during the first cycle of 
recruitment: data were collected on a retrospectively identified cohort from December 2009 
to October 2010 and the prospectively identified cohort between March 2010 and October 
2011. The retrospective cohort comprised patients with “established AF” (for at least 6, and 
up to 24 months before enrolment), who were identified retrospectively and then followed 
prospectively for 0-18 months (such that the total time of follow-up was 24 months from the 
day of diagnosis) (Figure 1). As mortality risk is higher in the early period after AF 
diagnosis,19 differences in the interval between AF onset and inclusion in a registry are likely 
to impact observed outcome rates (Figure 2). 
 
In the prospectively identified cohort, patients with “newly diagnosed AF” (enrolled within 6 
weeks of diagnosis) were followed prospectively until 24 months after the “first study visit”.  
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The term “first study visit” is the date that the patient was enrolled in GARFIELD-AF. 
Events recorded included stroke/SE, all-cause mortality, and bleeding (severity and location). 
Submitted data were audited for completeness and accuracy by the coordinating centre 
(Thrombosis Research Institute [TRI], London, UK). The GARFIELD-AF protocol requires 
that 20% of all electronic case report forms are monitored against source documentation, that 
there is an electronic audit trail for all data modifications, and that critical variables are 
subjected to additional audit.3  
 
Continuous variables are expressed as mean ± standard deviation (SD) or median (25th, 75th 
percentiles) and categorical variables as frequency and percentage. Only the first occurrence 
of each event was analysed. Occurrence of major clinical outcomes is described using the 
number of events, person-time event rate (per 100 person-years), and 95% confidence 
interval (CI). The Poisson model was used to estimate person-year rates, with the number of 
events as the dependent variable and the log of time as an offset, i.e., a covariate with a 
known coefficient of 1.   
 
Comparisons were made between the cohorts identified either retrospectively or 
prospectively and then followed prospectively from the date of first study visit. For the 
comparison of event rates between the two cohorts, we used the Mantel-Haenszel method to 
calculate the ratios and p values were derived by the Chi-square test.   
 
A landmark analysis of the prospectively collected patients was also generated, starting 
follow-up at 6 months after enrolment in the study.  This mortality rate illustrated the 
expected survival in patients who experienced AF for 6 months, making it more similar in 
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this respect to the retrospectively collected population. The rates of stroke/SE as well as the 
major bleed are recalculated in the subset of patients who survived to 6 months to simulate 
the retrospectively collected patients.  In this landmark analysis, follow-up for events is from 
the time of AF onset as in the retrospectively collected group. 
 
 
RESULTS 
Data were collected from December 2009 on 5069 patients who were retrospectively identified 
and 5501 from March 2010 who were prospectively identified. The mean (± SD) time from 
diagnosis to the first study visit was 60.6 (± 23.6) weeks in the retrospectively identified 
cohort and 1.8 (± 1.8) weeks in the prospectively identified cohort. The mean (± SD) follow-
up after the first study visit was 42.0 (± 23.9) weeks and 97.1 (± 40.8) weeks for each cohort, 
respectively. The mean (± SD) total duration from AF diagnosis to end of follow-up was 
102.4 (± 24.4) weeks and 98.9 (± 40.8) weeks for the retrospectively identified and 
prospectively identified patients, respectively. The number of patients lost to prospective 
follow-up was 210 (2.4%) and 321 (5.8%) in each cohort, respectively. 
 
Baseline demographic and clinical characteristics 
The baseline characteristics recorded during the first study visit are summarized in Table 1.  
Although some demographic features (age, sex, geographic distribution, and care setting) 
were similar for both cohorts, other features differed substantially. At the time of the first 
study visit, a greater proportion of patients from the retrospectively identified cohort with 
“established AF” had a confirmed diagnosis of permanent AF (36.3% vs. 14.1% of 
prospective patients); there was a great proportion with identified paroxysmal AF (30.9% vs. 
24.5% of prospective patients) and fewer had unclassified AF (13.3% vs. 44.8% of 
Downloaded from https://academic.oup.com/ehjqcco/article-abstract/doi/10.1093/ehjqcco/qcx030/4082930/Why-Are-Outcomes-Different-for-Registry-Patients
by St George's University of London user
on 29 September 2017
 9 
 
prospective patients) (Fig. 3). The retrospectively identified cohort also had a lower 
proportion with New York Heart Association (NYHA) class III-IV congestive heart failure 
(27.5% vs. 32.9%), but a higher proportion with a history of stroke (10.9% vs. 8.6%) or 
history of bleeding (3.8% vs. 3.1%) than the prospectively identified cohort with “newly 
diagnosed AF”. Despite these differences, the median (interquartile range) CHA2DS2-VASc 
score did not differ: 3.0 (2.0 to 4.0) and 3.0 (2.0 to 4.0), respectively for retro- and 
prospectively identified cohorts. 
 
Treatment patterns 
As shown in Fig. 4., antithrombotic therapies prescribed were broadly similar in both cohorts, 
with a slightly greater proportion of patients in the retrospectively identified cohort treated 
with oral anticoagulants (OACs) ± antiplatelet (AP) therapy (63.9% vs. 57.4%) and fewer 
receiving either AP lone therapy (26.9% vs. 30.2%) or no stroke prevention therapy (9.2% vs. 
12.4%). Analysis of patients with moderate-high risk of stroke (CHA2DS2-VASc score ≥2) 
found that patients refusal to take OACs was more likely in the retro- than the prospectively 
identified cohort: 9.8% vs. 6.0% (analyses based based on those who received no stroke 
prevention therapy, i.e.768 patients in the retro- and  893 patients in prospectively identified 
cohorts). 
 
Some differences in the prescribing of OACs were also observed between the cohorts, with 
more patients in the retrospectively identified cohort receiving vitamin K antagonist (62.1% 
vs. 53.2%) and fewer receiving non-vitamin K antagonist anticoagulants (NOACs) (1.8% vs. 
4.2%).  
 
Stroke and bleeding event rates  
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Stroke/SE rates per 100 person-years (recorded from the date of the first study visit up to 1 
year) were numerically higher in the retro- than the prospectively identified cohort (1.34 
[95% CI 1.00 to 1.79] vs. 1.07 [95% CI 0.82 to 1.39]), and the rate of major bleeding per 100 
person-years was similar in both cohorts (0.72 [95% CI 0.49 to 1.07] vs. 0.82 [95% CI 0.60 to 
1.10]). These differences were not statistically significant: p=0.257 and p=0.624, respectively  
(Fig. 4.).  When evaluating event rates per 100 person-years up to 2 years, non-significant 
differences between the retro- and prospectively identified cohorts were also observed for 
stroke/SE (1.21 [95% CI 0.91 to 1.60] vs. 1.03 [95% CI 0.85 to 1.25], respectively; p=0.362) 
and for major bleeding  (0.65 [95% CI 0.44 to 0.95] vs. 0.72 [95% CI 0.57 to 0.91], 
respectively; p=0.662).  
   
 
All-cause mortality 
All-cause mortality rates per 100 person-years during the prospective follow-up (starting 
from the date of the first study visit up to 1 year) were significantly lower in patients 
retrospectively identified compared with prospectively identified: 3.04 (95% CI 2.51 to 3.67) 
vs. 4.05 (95% CI 3.53 to 4.63); p=0.016 (Fig. 5.). These differences were also observed for 
all-cause mortality rates per 100 person-years evaluated up to 2 years: 2.95 (95% CI 2.46 to 
3.53) vs. 3.67 (95% CI 3.30 to 4.07); p=0.039 in the retro- and prospectively identified 
cohorts, respectively. 
 
In order to take account of the higher mortality rate over the first 6 months after diagnosis, a 
further analysis was conducted to compare the cohort identified retrospectively (and followed 
prospectively from the date of first study visit) with the cohort identified prospectively but 
excluding all patients who died within 6 months; thus  follow-up started  at 6 months (Fig. 
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5b).  These analyses found that all-cause mortality rates per 100 person-years between the 
cohorts were similar: 3.04 (95% CI 2.51 to 3.67) vs. 3.54 (95% CI  2.9 to 4.37)  for the 
retrospective cohort vs. the prospectively identified cohort, excluding patients who died 
within 6 months of the first visit (Fig. 5b) 
 
DISCUSSION 
Interpretations of data from registries that aim to evaluate the characteristics and outcomes of 
patients with AF need to account for differences in registry design, and in particular, the 
survivorship bias that is incurred with retrospective enrolment. The timing of the analysis in 
relation to the natural history of the disease and also the extent of exposure to stroke 
prevention therapies (such as antithrombotics) and adherence to these therapies are critical to 
the interpretation of outcomes. 
 
These analyses demonstrate differences in outcome between retrospectively versus 
prospectively identified patients with AF and the findings are relevant to the interpretation of 
other registries where the methods of data collection are retrospective (such as the DANISH 
national registry20), or those that identify patients with established AF (PREFER, EORP)11, 21, 
versus prospective studies on newly identified AF (GARFIELD, GLORIA, ORBIT, 
RECORD)3, 14, 15, 22. The significant decrease in events from retrospectively compared with 
the prospective cohort may be due in part to survivor bias. We have seen from our own 
analyses and also from the Framingham Heart study that there is an increased hazard for 
dying soon after the onset of AF.19, 23 These patients did not survive to enter the 
retrospectively identified cohort but were in the prospective identified cohort (Fig. 2.). As a 
consequence, the data show that the retrospectively identified cohort of patients had different 
characteristics compared to the prospective identified cohort patients.  For example, patients 
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with more severe comorbid conditions (NYHA class III-IV congestive heart failure) at the 
time of diagnosis, who died before the study start date, were not included in the analyses of 
patients who were restrospectively identified (see Fig. 2.), with a consequent under-
representation of these comorbidities at baseline.   
 
The study also found a trend (not statistically significant) for differences in the unadjusted 
stroke rates in the prospectively identified cohort with “newly diagnosed AF” compared with 
retrospectively identified cohort with “established AF”. This may reflect the natural history 
of the disease. For example, patients in the retrospectively identified cohort were more likely 
to have permanent or persistent AF (in greater than half of the patients); they also showed a 
greater prevalence of prior stroke, moderate-to-severe chronic kidney disease, and prior 
major bleed than prospectively identified cohort (in whom the median time since diagnosis of 
AF  was 1.8 weeks). It is likely that the progressive nature of cardiovascular disease increases 
the stroke risk over time after the diagnosis of AF.24-27  Other factors, such as non-adherence 
to OAC, tend to increase over time after the initial critical period at the diagnosis of AF 
(when patients are most compliant).28 Thus, the time period of evaluation of AF, in relation to 
its onset, may be of key importance in the interpretations of these findings. 
 
The introduction of NOACs in Europe in 2010 was associated with a change in prescribing 
practice.29, 30 We observed a slight shift in treatment patterns between prospectively identified  
patients enrolled between March 2010 and October 2011 and those from the retrospectively 
identified patients (evaluated between December 2009 and October 2011). Overall, 
prospectively identified  patients with a new diagnosis of AF  (including a greater proportion 
with paroxysmal AF) were more likely to receive either AP therapy alone or no 
antithrombotic therapy. There was a small increment in NOAC prescribing.  Fewer patients 
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with a moderate-to-high risk of stroke refused OAC treatment with the recruitment of patients 
into the prospective cohort (compared with the retrospectively identified cohort).   
 
Both the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with 
Atrial Fibrillation (GLORIA-AF) and GARFIELD-AF focus on newly diagnosed patients 
(within 12 and 6 weeks of diagnosis, respectively), and both evaluate treatment during the 
period in which patients are at the highest risk of stroke. However, GLORIA excludes those 
who have a life expectancy of <1 year at the time of enrolment as well as patients with a 
medical condition other than AF for which chronic use of VKAs is indicated.22 By contrast, 
GARFIELD-AF is without exclusions due to comorbidities or treatments.17 Only a small 
proportion of patients in GARFIELD-AF (~5.0%) were lost to the prospective follow-up over 
2 years.  
 
In conclusion, interpretations of data from AF registries and observational cohorts need to 
take account of potential sources of bias relating to survivorship and recall, as well as the 
collection of data in relation to the time from the onset of AF. The analysis of retrospective 
and prospectively identified data from GARFIELD-AF reveals the potential differences in 
characteristics and outcomes where the patient enrolment begins retrospectively. For these 
reasons, a prospective study design was selected for sucessive cohorts of GARFIELD-AF as 
the most reliable way of capturing the burden of disease from an unselected population 
shortly after the diagnosis of AF. 
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[Table] 
Table 1. Baseline characteristics of patients enrolled retrospectively and prospectively from 
cohort 1 of the GARFIELD-AF registry 
  Retrospectively 
enrolled cohort 
(N=5069) 
Prospectively  
enrolled cohort 
(N=5501) 
Female, n/N (%) 2159/5069 (42.6) 2402/5501 (43.7) 
Age at diagnosis (years), median (IQR) 71.0 (63.0 to 77.0) 71.0 (63.0 to 78.0) 
Time since AF diagnosis (weeks), 
median (IQR) 
57.1 (39.2 to 80.5) 1.8 (0.7 to 3.7) 
Systolic BP (mm Hg), median (IQR) 132.0 (120.0 to 145.0) 130.0 (120.0 to 145.0) 
LVEF <40%, n/N (%) 277/2837 (9.8) 304/3314 (9.2) 
Type of AF diagnosed at start of study, 
n/N (%) 
  
    Unclassified 676/5065 (13.3) 2465/5499 (44.8) 
    Paroxysmal 1567/5065 (30.9) 1347/5499 (24.5) 
    Persistent 982/5065 (19.4) 909/5499 (16.5) 
    Permanent 1840/5065 (36.3) 778/5499 (14.1) 
Congestive heart failure NYHA class, 
n/N (%) 
  
    I 167/910 (18.4) 183/993 (18.4) 
    II 493/910 (54.2) 483/993 (48.6) 
    III 211/910 (23.2) 271/993 (27.3) 
    IV 39/910 (4.3) 56/993 (5.6) 
Table
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Coronary artery disease, n/N (%) 963/5065 (19.0) 1059/5499 (19.3) 
Acute coronary syndromes, n/N (%) 487/5065 (9.6) 553/5499 (10.1) 
Stroke, n/N (%) 550/5065 (10.9) 472/5499 (8.6) 
History of bleeding, n/N (%) 195/5065 (3.8) 172/5499 (3.1) 
History of hypertension, n/N (%) 3986/5065 (78.7) 4224/5499 (76.8) 
Hypercholesterolaemia, n/N (%) 2114/5065 (41.7) 2027/5499 (36.9) 
Diabetes, n/N (%)   
    No 3959/5064 (78.2) 4284/5499 (77.9) 
    Type I 47/5064 (0.9) 57/5499 (1.0) 
    Type II 1058/5064 (20.9) 1158/5499 (21.1) 
Chronic kidney disease – moderate-to-
severe grade, n/N (%) 
529/5065 (10.4) 495/5483 (9.0) 
CHA2DS2-VASc score
*   
    Mean (SD) 3.2 (1.6) 3.2 (1.6) 
    Median (IQR) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 
HAS-BLED score†   
    Mean (SD) 1.5 (1.0) 1.5 (0.9) 
    Median (IQR) 1.0 (1.0 to 2.0) 1.0 (1.0 to 2.0) 
 
AF, atrial fibrillation; BP, blood pressure; IQR, interquartile range; LVEF, left ventricular 
ejection fraction; NYHA, New York Heart Association; SD, standard deviation 
Missing from the analyses: * established AF (159); newly diagnosed AF (94); † established 
AF (2037); newly diagnosed AF (1961) 
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[Figure Legends] 
       Figure 1. Description of time-to-event analyses relative to enrolment and diagnosis of atrial 
fibrillation 
AF, atrial fibrillation 
Figure 2. Schematic representation of the study design. The figure illustrates patients 
enrolled either retrospectively or prospectively in relation to survival over the time period 
from diagnosis of atrial fibrillation. The red lines indicate the patients who died in our 
schema (not actual data). These patients would be missing from the data collected 
retrospectively, but included in the data from patients enrolled prospectively. 
Figure 3. Type of AF at first study visit in patients with established AF enrolled 
retrospectively or newly diagnosed AF enrolled prospectively 
Figure 4. Antithrombotic treatment for patients in the retrospectively enrolled cohort 
(n=5069) or the prospectively enrolled cohort (n=5501) 
AP, antiplatelet; DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, vitamin K 
antagonist.  
Figure 5. Summary of event rates and 95% confidence intervals (per 100 person-years) for 
data collected prospectively a. starting from the date of the first study visit up to 1 year                 
b. Mortality is based on a landmark analysis, which excluded all patients who died within 6 
months and follow-up starts at 6 months (day 183).  Event rates for stroke/SE and for major 
bleed are in the subset of patients who survived to 6 months, but start follow-up at the time of 
AF onset.  
SE, systemic embolism; AF, atrial fibrillation 
 
Figure legends
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